ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.002,02
-1,43%
S&P 500
5.431,60
-0,04%
Dow Jones
38.589,16
-0,15%
Euro vs US Dollar
1,07175
0,00%
Bitcoin
66.569,30
0,57%
Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Lipocine Inc (LPCN)

  7. Lipocine Inc (LPCN) News

LPCN

Lipocine (LPCN)

Lipocine Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:LPCN
DatumZeitQuelleÜberschriftSymbolFirma
10/06/202415h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPCNLipocine Inc
10/06/202414h00PR Newswire (US)Lipocine Presents 52 Week Results from LPCN 1148 Phase 2 Study in Late Breaking Session at EASL Congress 2024NASDAQ:LPCNLipocine Inc
07/06/202423h48Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LPCNLipocine Inc
07/06/202423h45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LPCNLipocine Inc
07/06/202423h43Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LPCNLipocine Inc
07/06/202423h41Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LPCNLipocine Inc
07/06/202423h39Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LPCNLipocine Inc
05/06/202422h32Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPCNLipocine Inc
03/06/202423h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPCNLipocine Inc
03/06/202423h09Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:LPCNLipocine Inc
09/05/202414h00PR Newswire (US)Lipocine Announces Financial Results for the First Quarter Ended March 31, 2024NASDAQ:LPCNLipocine Inc
09/05/202412h06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LPCNLipocine Inc
09/05/202412h03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPCNLipocine Inc
08/05/202414h00PR Newswire (US)Lipocine Announces Late Breaking Oral Presentation of Data from the Phase 2 Study of LPCN 1148 at EASL Congress 2024NASDAQ:LPCNLipocine Inc
08/05/202412h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPCNLipocine Inc
01/05/202414h00PR Newswire (US)Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154NASDAQ:LPCNLipocine Inc
11/04/202413h00PR Newswire (US)Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with ObesityNASDAQ:LPCNLipocine Inc
28/03/202413h00PR Newswire (US)Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with CirrhosisNASDAQ:LPCNLipocine Inc
25/03/202413h00PR Newswire (US)Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154NASDAQ:LPCNLipocine Inc
07/03/202423h31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPCNLipocine Inc
07/03/202414h00PR Newswire (US)Lipocine Announces Financial Results for the Full Year Ended December 31, 2023NASDAQ:LPCNLipocine Inc
07/03/202412h08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPCNLipocine Inc
07/03/202412h07Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:LPCNLipocine Inc
06/03/202414h00PR Newswire (US)Lipocine to Present at 36th Annual Roth ConferenceNASDAQ:LPCNLipocine Inc
06/03/202412h01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPCNLipocine Inc
12/02/202422h10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPCNLipocine Inc
06/02/202414h00PR Newswire (US)Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154NASDAQ:LPCNLipocine Inc
02/02/202414h00PR Newswire (US)Lipocine Announces Continued Commercialization of TLANDO® through Verity PharmaceuticalsNASDAQ:LPCNLipocine Inc
18/01/202414h20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPCNLipocine Inc
18/01/202414h00PR Newswire (US)Lipocine and Verity Pharma Enter into License Agreement for TLANDO® Franchise in the U.S. and CanadaNASDAQ:LPCNLipocine Inc
 Showing the most relevant articles for your search:NASDAQ:LPCN

Kürzlich von Ihnen besucht

AMEX
XLE
Energy Select Sector SPDR
DBI
DAX
DAX
NASDAQ
AAPL
Apple
NYSE
DIS
Walt Disney
TG
TUI1
Tui
PM
XAUUSD
Gold vs US Dollar
DBI
SDXP
SDAX
AMEX
XLF
Financial Select Sector
TG
D7G
Nel ASA
TG
RHM
Rheinmetall
NASDAQ
GOOGL
Alphabet
CCOM
US500
US 500
CCOM
SILVER
SILVER
USOTC
BNPQY
BNP Paribas (QX)
NYSE
XOM
Exxon Mobil
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten